Recent advances in cardiovascular science indicate that inflammatory processes play an important role in the etiology of cardiovascular diseases. This fact has led to the discovery of novel inflammatory biomarkers, which may easily be used as additional screening tools for the identification of individuals at increased risk of coronary heat disease. In this way, this biomarker identification can be used as a screening tool for general population. Moreover, this blood test will help a lot in early detection of individuals at an increased risk of cardiovascular diseases and the preventive or the therapeutic therapy can be initiated a bit early.
One such novel inflammatory biomarker is lipoprotein associated phospholipase A. The levels of lipoprotein associated phospholipase are detected through PLAC test. The test detects high levels of the protein lipoprotein-associated phospholipase A2 (Lp-Pla2) which is more common in stroke patients.
Various studies are available which proved that the PLAC test provides new information, over and above traditional risk factors, that can guide physicians and patients to make the necessary changes that may prevent patients from suffering cardiovascular diseases and events such as stroke and heart attack.
A recent study done on 12,773 people for about 6 years, found that the levels of the protein were higher in the stroke cases than in people who did not have one.